Finanzen von Denali Therapeutics Inc (DNLI)DNLIDenali Therapeutics Inc

Evaluating the bottom line, Denali Therapeutics Inc. maintains a gross margin of 76.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3622.11%, while the net margin is -3539.21%. These profitability ratios, combined with a Return on Equity (ROE) of -54.93%, provide a clear picture of how effectively DNLI converts its operational activities into shareholder value.

In the context of the broader market, DNLI competes directly with industry leaders such as TNGX and RCUS. With a market capitalization of $3.90B, it holds a significant position in the sector. When comparing efficiency, DNLI's gross margin of 76.61% stands against TNGX's N/A and RCUS's 100.00%. Such benchmarking helps identify whether Denali Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Denali reported a Q2 2026 loss of $0.68 per share, better than the consensus estimate of $0.73, and a gross margin of 76.61%, suggesting effective cost management and potential for profitability as revenues grow.